Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03211065 · ClinicalTrials.gov registry record · Phase 2
Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig
A Phase 2 study, sponsored by Rochester General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03211065 is a Phase 2 study that has completed, run by Rochester General Hospital. The registered enrollment target is 16 participants.
The verdict
NCT03211065, a Phase 2 study, has completed, sponsored by Rochester General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal immune system putting them at increased risk of infection.
Interventions
- DRUG 20% subcutaneous immunoglobulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-07-21 |
| Est. Completion | 2019-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03211065
The ClinicalTrials.gov registry entry for NCT03211065 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rochester General Hospital, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 20% subcutaneous immunoglobulin is the first listed.
NCT03211065 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03211065 about?
NCT03211065 is a clinical study titled "Humoral Immunodeficiency With Rituximab and Therapy With Subcutaneous Ig". To study the use of subcutaneous (injected under the skin) immunoglobulin replacement therapy (replacement of antibodies, which are infection-fighting proteins) in patients with a type of blood cancer called lymphoma, who have been treated with rituximab (a type of chemotherapy) and have an abnormal...
What is the current status of trial NCT03211065?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2017-07-21. Estimated completion is 2019-11-01.
What interventions are being tested in trial NCT03211065?
The interventions under investigation include: 20% subcutaneous immunoglobulin (DRUG).
Who is sponsoring clinical trial NCT03211065?
This trial is sponsored by Rochester General Hospital, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.